Horizon Therapeutics' (HZNP) Tepezza Sales Rebound in April, Commentary from the Jefferies Healthcare Conference

Jefferies analyst David Steinberg reiterated a Buy rating and $120.00 price target on Horizon Therapeutics (NASDAQ: HZNP) after management noted that the Tepezza reintroduction has gained momentum, with 75% of disrupted patients now restarted vs 50% a month ago, at the Jefferies Healthcare Conference.

The analyst commented "Mgt indicates that flagship TED drug Tepezza is regaining momentum following the Q1 supply shortage. They noted that ~75% of the disrupted patients have now either restarted or are scheduled to reinitiate treatment vs ~50% disclosed on the Q1 call a month ago. Importantly, they noted that April was the strongest month since launch for patient enrollment form (PEF) generation, positioning Q3 as the largest Tepezza rev quarter this year."

For an analyst ratings summary and ratings history on Horizon Therapeutics click here. For more ratings news on Horizon Therapeutics click here.

Shares of Horizon Therapeutics closed at $88.24 yesterday.

You May Also Be Interested In

• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald
• UBS Reiterates Buy Rating on HF Sinclair (DINO)